{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"41.0","value":"0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"23.2","value":"0"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"45.9","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"Overall response rate is the best response of complete response (CR) or partial response (PR) as classified by the independent central review according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants per cohort with at least 1 measurable lesion, multiplied by 100. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 8 mg/kg Ramucirumab administered as an intravenous infusion Q2W with 3 doses per 42 day cycle.","id":"OG000","title":"8 mg/kg Ramucirumab (Part A)"},{"description":"Participants received 12 mg/kg Ramucirumab as an intravenous injection Q2W with 3 doses per cycle.","id":"OG001","title":"12 mg/kg Ramucirumab (Part A)"},{"description":"Participants received 12 mg/kg Ramucirumab as an intravenous injection Q2W with 3 doses per cycle.","id":"OG002","title":"12 mg/kg Ramucirumab (Part B)"}],"paramType":"NUMBER","populationDescription":"All randomized participants who received at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"Baseline to Date of Objective Disease Progression (Up to 42 Months)","title":"Overall Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}